Editorial
|
|
|
|
|
Irrational approval of asenapine
|
|
|
|
Marketing Authorisations
|
|
|
|
|
A less effective, yet more dangerous, neuroleptic!
|
|
|
|
|
|
|
|
|
|
Too dangerous in medullary thyroid cancer
|
|
|
|
|
|
|
|
|
|
Many adverse effects and uncertain benefit
|
|
|
|
|
|
|
|
|
|
Still graduated in ml in the EU
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Poor knowledge of use and design flaws
|
|
|
|
|
|
|
|
|
|
Preventing unintentional adrenaline injection with autoinjectors
|
|
|
|
|
|
|
|
|
|
|
|
Prolonged symptoms of overdose
|
|
|
|
|
|
|
|
|
|
A very severe case report
|
|
|
|
|
|
|
|
|
|
An analysis of reports in the USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In young adults and adolescents
|
|
|
|
|
|
Reviews
|
|
|
|
|
Watchful waiting, surgery or radiation therapy
|
|
|
|
|
|
|
|
|
|
|
|
Treatment of localised prostate cancer: inform patients about adverse effects
|
|
|
|
|
|
|
|
|
|
|
|
Belgian health technology assessment
|
|
|
|
Outlook
|
|
|
|
|
A response to the European Medicines Agency
|
|
|
|
|
|
|
|
|
|
Profits not dependent on therapeutic advance
|
|
|
|
|
|